December 14, 2023.

Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study.

More than 200 patients were recruited in a multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders.

November 16, 2023.

An editorial published in the journal Alimentary Pharmacology and Therapeutics describes Atmo Biosciences’ gas-sensing capsule as disruptive technology that has enabled unlocking of key aspects of microbial metabolism, especially with respect to carbohydrate fermentation.

August 10, 2023.

Atmo Biosciences today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.

The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation (slow transit through the colon).